Skip to main content
. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202

Table 2.

Postdose 1 seroconversion rates between the MMRV/MMRV group and pooled MMR/MMRV+MMR/MMR+V groups (ATP cohort)

MMRV
MMR
(MMRV/MMRV group)
(Pooled (MMR/MMRV)+ (MMR/MMR+V) groups) Difference in percentage (MMRV−MMR)
Antibody N* Per cent† N* Per cent† Per cent‡ (95% CI)
Measles 148 93.2 225 88.0 5.24 (−1.06 to 11.13)
Mumps 144 86.1 224 83.9 2.18 (−5.66 to 9.42)
Rubella 149 98.7 225 99.6 −0.90 (−4.36 to 1.29)
Varicella 138 94.2 ­

*Number of children initially seronegative with available results.

†Percentage of children who seroconverted for each antigen.

‡Difference in percentage of children who seroconverted for each antigen between the MMMR/MMRV group and the pooled MMR results from the (MMR/MMRV+MMR/MMR+V) groups.

ATP, according-to-protocol; MMR, measles-mumps-rubella vaccine; MMRV, measles-mumps-rubella-varicella vaccine; MMR+V, MMR+varicella vaccine.